News | October 01, 2013

Siemens Receives 2013 North American Frost & Sullivan Award for Company of the Year

Siemens, Siemens logo, Siemens Healthcare

October 1, 2013 — Based on its recent analysis of the molecular imaging market, Frost & Sullivan recognizes Siemens Healthcare with the 2013 North American Frost & Sullivan Award for Company of the Year. Siemens Healthcare has dedicated equal attention and resources to the development of both single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging – the two pillars of molecular imaging. The company has moved quickly to innovate and strategize in a rapidly evolving market to secure for itself an ideal market position.

Siemens Healthcare has made breakthrough technological innovations in the SPECT market, but what is truly impressive is that it accomplished this in a rather saturated, low-turnover market for new equipment purchases. It has made similar advances in PET imaging, and has been at the forefront of the most promising clinical applications in oncology, neurology, and cardiology.

As new PET radiopharmaceutical agents for use in the evaluation of Alzheimer's and other cognitive diseases gain approval by the U.S. Food and Drug Administration (FDA), Siemens Healthcare’s early efforts have allowed the company to promptly design and deliver the industry’s first end-to-end amyloid PET imaging solution. By combining the equipment and software advances of the new syngo.PET amyloid plaque solution with the reliable manufacturing and distribution network of Siemens’ PETNET Solutions, Siemens has become the PET solution provider of choice in neurology.

“Having recognized many years ago that the future of medical imaging would hinge on more advanced and efficient hybrid imaging modalities, Siemens Healthcare has built a legacy of industry firsts,” said Frost & Sullivan Industry Principal Nadim Michel Daher. “Today, as the result of this continuous technology and product advancement, Siemens Healthcare is leading the way in the imaging industry with regard to each of the SPECT/CT, PET/CT and PET/MR imaging modalities.”

In PET/CT imaging, the enhanced capabilities and image resolution of the new Biograph mCT Flow now enable physicians to rely on molecular imaging with accurate and reproducible quantification. Siemens’s groundbreaking FlowMotion technology, which goes beyond the traditional stop-and-go image acquisition technique by offering a continuous flow motion of the patient table, is yet another technological enabler. Similarly, in SPECT/CT, the xSPECT technology-based Symbia Intevo empowers nuclear medicine and is a game-changer. xSPECT is a novel reconstruction technique that extends beyond attenuation correction to use voxel-based registration of both the SPECT and CT datasets.

“The ongoing cycles of product and technology innovation within each sub-specialty field allow Siemens’s current and prospective customers to make more collaborative equipment purchases,” noted Daher. “This multi-specialty approach to imaging might still be an emerging best practice used by avant-garde providers today, but it is slated to become the new standard of care for providers. Siemens’ molecular imaging customers will be better equipped during this reshaping of the clinical and business models for molecular imaging.”

In addition to its leadership in the premium-tier product segments, Siemens Healthcare also has polished its entry-level offerings to cater to the mid-tier and value-based customer segments. The company continues to make its molecular imaging product portfolio more modular, enabling a more cost-effective and phased adoption of high-end technology by various types of providers.

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in terms of growth strategy and implementation. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.

For more information: www.frost.com

Related Content

CT Decision Instrument Reliably Guides Pediatric Blunt Trauma imaging Decisions

This is a four-site prospective observational cohort. Image courtesy of Kirsty Challen, B.Sc., MBCHB, MRES, Ph.D., Lancashire Teaching Hospitals, United Kingdom.

News | Clinical Decision Support | July 18, 2018
A new study finds The Pediatric NEXUS Head Computed Tomography (CT) Decision Instrument (DI) reliably identifies blunt...
Artificial Intelligence Provides Faster, Clearer MRI Scans

A new artificial-intelligence-based approach to image reconstruction, called AUTOMAP, yields higher quality images from less data, reducing radiation doses for CT and PET and shortening scan times for MRI. Shown here are MR images reconstructed from the same data with conventional approaches, at left, and AUTOMAP, at right. Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital

News | Artificial Intelligence | July 17, 2018
A research team with funding from the National Institute for Biomedical Imaging and Bioengineering (NIBIB) has...
Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
iSchemaView Brings RAPID Imaging Platform to Australia and New Zealand
News | Stroke | July 13, 2018
iSchemaView has signed Diagnostic Imaging Australia (DIA) to be the exclusive distributor for the RAPID cerebrovascular...
Neural Analytics Inc. Receives CE Mark for Robotic Ultrasound System
Technology | Ultrasound Imaging | July 03, 2018
Medical robotics company Neural Analytics Inc. announced that it received CE Mark for its NeuralBot System, a robotic...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Dictum Health Launches Advanced Telestroke Module for Virtual Exam Room Platform
Technology | Teleradiology | June 28, 2018
Dictum Health Inc., creators of the Virtual Exam Room (VER) telehealth technology, announced the release of their Care...
Overlay Init